Skip to main content
OpenTrials
Completed

NCT Number: NCT00633074

Non-inferiority Study of GSK Biologicals' Influenza Vaccine GSK576389A Using Different Formulations

The purpose of this study is to show the non-inferiority of different formulations of GlaxoSmithKline Biologicials' influenza vaccine.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Influenza Infections Influenza, Human Orthomyxoviridae Infections RNA Virus Infections Respiratory Tract Diseases Respiratory Tract Infections Virus Diseases

Age range

65 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

GSK Investigational Site, Saku, Estonia

Loading trial locations.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subjects who the investigator believes that they can and will comply with the requirements of the protocol should be enrolled in the study.
  • A male or female 65 years of age or older at the time of vaccination.
  • Written informed consent obtained from the subject.
  • Free of an acute aggravation of the health status as established by clinical evaluation (medical history and medical history directed examination) before entering into the study.

Exclusion criteria

  • Suspected (based on clinical symptoms) or confirmed (based on laboratory results) influenza infection within the last 6 months.
  • Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine, or planned use during the study period.
  • Administration of other licensed vaccines within 2 weeks (for inactivated vaccines) or 4 weeks (for live vaccines) prior to enrolment in this study. Planned administration of a vaccine not foreseen by the study protocol up to 21 days after vaccination.
  • Planned administration of an influenza vaccine other than the study vaccines during the entire study period.
  • Previous vaccination against influenza with any seasonal vaccine since July 2007.
  • Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to the first vaccine dose.
  • Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.
  • History of hypersensitivity to a previous dose of influenza vaccine.
  • History of allergy or reactions likely to be exacerbated by any component of the vaccine(s) including egg and chicken protein.
  • Acute (active) clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by clinical evaluation (medical history and medical history directed physical examination) or pre-existing laboratory screening tests.
  • Acute disease at the time of enrolment.
  • Administration of immunoglobulins and/or any blood products within the three months preceding the first dose of study vaccine or planned administration during the study period.
  • Any medical conditions in which IM injections are contraindicated

Treatment and study plan

Thiomersal-free FluAS25 adjuvanted vaccine (GSK576389A)

Biological

Intramuscular administration, 1 dose

Thiomersal reduced FluAS25 adjuvanted vaccine (GSK576389A)

Biological

Intramuscular administration, 1 dose

Primary outcomes

  1. Serum Haemagglutination-inhibition (HI) Antibody Titer Against the Three Vaccine Strains

    Time frame: Days 0 and 21

    Titers were expressed as Geometric Mean Titers (GMTs). The three vaccine strains assessed included A/Solomon Islands, A/Wisconsin and B/Malaysia.

Secondary outcomes

  1. Number of Subjects Seropositive for HI Antibodies Against the Three Vaccine Strains

    Time frame: Days 0 and 21

    A seropositive subject was defined as a subject with a serum HI titer greater than or equal to 1:10. The three vaccine strains assessed included A/Solomon Islands, A/Wisconsin and B/Malaysia.

  2. Number of Subjects Seroconverted for HI Antibodies Against the Three Vaccine Strains

    Time frame: Day 21

    A seroconverted subject was defined as a subject who had either a pre-vaccination titer below 1:10 and a post-vaccination titer greater than or equal to 1:40 or a pre-vaccination titer greater than or equal to 1:10 and at least a four-fold increase in post-vaccination titer. The three vaccine strains assessed included A/Solomon Islands, A/Wisconsin and B/Malaysia.

  3. HI Antibody Seroconversion Factors

    Time frame: Day 21

    Seroconversion factor was defined as the fold increase in serum HI GMTs post-vaccination compared to Day 0. The three vaccine strains assessed included A/Solomon Islands, A/Wisconsin and B/Malaysia.

  4. Number of Subjects Seroprotected for HI Antibodies Against the Three Vaccine Strains

    Time frame: Days 0 and 21

    A seroprotected subject was defined as a suject with a serum HI titer greater than or equal to 1:40 that usually is accepted as indicating protection.

  5. Number of Subjects Reporting Any and Grade 3 Solicited Local Symptoms

    Time frame: During a 7-day period after vaccination

    Solicited local symptoms assessed include ecchymosis, pain, redness and swelling. Any: any symptom regardless of intensity grade. Grade 3 pain: considerable pain at rest, which prevented normal everyday activities. Grade 3 ecchymosis, redness and swelling: more than 100 millimeter.

  6. Duration of Solicited Local Symptoms

    Time frame: During a 7-day period after vaccination

    Duration was expressed as median number of days the symptom persisted. Solicited local symptoms assessed include ecchymosis, pain, redness and swelling.

  7. Number of Subjects Reporting Any, Grade 3 and Related Solicited General Symptoms

    Time frame: During a 7-day period after vaccination

    Solicited general symptoms assessed include arthralgia, fatigue, headache, myalgia, nausea, shivering and fever. Any: any symptom regardless of intensity grade; any fever: oral temperature greater than or equal to 38 degrees Celsius (°C). Grade 3: symptoms that prevented normal activity ; Grade 3 fever: oral temperature greater than 39°C. Related: symptom assessed by the investigator as causally related to the study vaccination.

  8. Duration of Solicited General Symptoms

    Time frame: During a 7-day period after vaccination

    Duration was expressed as median number of days the symptom persisted. Solicited general symptoms assessed include arthralgia, fatigue, headache, myalgia, nausea, shivering and fever.

  9. Number of Subjects Reporting Any, Grade 3 and Related Unsolicited Adverse Events (AEs)

    Time frame: During a 21-day period after vaccination

    Unsolicited AE covers any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms.

  10. Number of Subjects Reporting Any, Grade 3 and Related Medically Significant Conditions (MSCs)

    Time frame: During a 21-day period after vaccination

    Medically Significant Conditions (MSCs) included all unsolicited adverse events that resulted in a medically attended visit.

  11. Number of Subjects Reporting Any and Related Serious Adverse Events (SAEs)

    Time frame: During the entire study period (up to Day 21)

    SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.

Sponsors and collaborators

Lead sponsor

GlaxoSmithKline

Industry

Registry information

Official study title

Non-inferiority Study of GlaxoSmithKline Biologicals' Influenza Vaccine GSK576389A Using Different Formulations.

Important dates

Study start
2008
Primary completion
2008
Study completion
2008
First posted
Mar 11, 2008
Registry last updated
Jun 8, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.